Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age

Vaccination offers the best way to prevent invasive meningococcal disease (IMD). As demonstrated in countries with national immunization programs (NIPs) against IMD, meningococcal conjugate vaccines have contributed to significant declines in incidence. Since some meningococcal vaccines are associat...

Full description

Bibliographic Details
Main Authors: Gary S. Marshall, Stephen I. Pelton, Corwin A. Robertson, Philipp Oster
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
immunogenicity
invasive meningococcal disease
imd
menacwy-crm
menacwy-d
menacwy-tt
menacyw-tt
menquadfi
meningococcal conjugate vaccine
safety
vaccine recommendations
Online Access:http://dx.doi.org/10.1080/21645515.2022.2099142

Similar Items

Similar Items